Intrinsiqq
Calidi Biotherapeutics Inc. logo

Calidi Biotherapeutics Inc.

CLDI

Compare

Valuation & Multiples

Based on TTM earnings · Diluted shares

Market Cap$2M
EPS$0.04
P/E11.94
P/FCF–
EV/EBITDA0.09
FCF Yield–
Div. Yield–
Net Debt/FCF–
Calidi Biotherapeutics Inc. intrinsic value
52-Week Range
$0.10$1.43

Profitability & Returns

Revenue

N/A

Net Income (TTM)

-$16M

▲ +10.1% YoY

Op. Margin

–

ROIC

-253.18%

▲ +4.3pp YoY

Cash Flow & Balance Sheet

FCF

N/A

Op. Cash Flow (TTM)

-$16M

▼ -8.1% YoY

Net Debt

-$3M

Net Cash Position

Cash & Equiv.

$4M

Continue Research

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with CLDI

CompareIntrinsic value
INMBInmune Bio Inc.
$0.83-7.49%10
BCDABioCardia, Inc.
$0.79+2.60%26
ENZNViskase Holdings, Inc.
$4.35-1.14%0
SNTISenti Biosciences Inc.
$2.79-2.82%0
ALLOAllogene Therapeutics Inc.
$0.63-6.31%10
EXOZExozymes Inc.
$2.91-14.05%10
AIMAIM ImmunoTech Inc.
$0.11-4.50%25
CADLCandel Therapeutics Inc.
$5.04-1.75%10

Calidi Biotherapeutics (CLDI) in three numbers

Quality score
19/100
Best check: net debt, -$3M. Weakest: return on capital, -253.2%.
Quality
Dividend
None
No dividend in the SEC filings we hold.
Dividends
P/E
11.94
From the last twelve months of earnings.
Financials

Questions about Calidi Biotherapeutics

Is Calidi Biotherapeutics (CLDI) overvalued?

Calidi Biotherapeutics trades at 11.94 times earnings. Intrinsiqq's fair value calculator has no opening value for CLDI, so weigh those multiples against the company's own history and the peers above. See how to tell if a stock is overvalued.

Is Calidi Biotherapeutics a high-quality business?

Calidi Biotherapeutics scores 19 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 3 checks computed from SEC filings. Its best check is net debt at -$3M, and its weakest is return on capital at -253.2%. The Quality tab shows every check against its target.

Does Calidi Biotherapeutics (CLDI) pay a dividend?

No. Calidi Biotherapeutics (CLDI) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.

Source: 10-Q filed 11 Nov 2026 (period ending 30 Sept 2026), SEC. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.

Spot a number that looks wrong? Check it in CLDI's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing CLDI

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.